Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dolores J Schendel

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Expert Opinion on Biological Therapy|January 26, 2007
Dendritic cell vaccine strategies for renal cell carcinomaDolores J Schendel
Haematologica|October 12, 2012
Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?Dolores J Schendel
Frontiers in Oncology|October 9, 2023
Evolution by innovation as a driving force to improve TCR-T therapiesDolores J Schendel
European Journal of Cell Biology|March 29, 2011
Third generation dendritic cell vaccines for tumor immunotherapyBernhard Frankenberger, Dolores J Schendel
Oncoimmunology|March 14, 2013
Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicityDolores J Schendel, Bernhard Frankenberger
Oncoimmunology|December 25, 2012
High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find themSusanne Wilde, Dolores J Schendel
Human Immunology|March 28, 2002
Allogeneic MHC class I ligands and their role in positive and negative regulation of human cytotoxic effector cellsChristine S Falk, Dolores J Schendel
Seminars in Cancer Biology|July 28, 2007
Immune suppression in renal cell carcinomaBernhard Frankenberger, Elfriede Noessner, Dolores J Schendel
Medical Sciences (Basel, Switzerland)|January 21, 2026
UniTope & TraCR: A Universal Tool to Tag, Enrich, and Track TCR-T Cells and Therapeutic ProteinsKanuj Mishra, Barbara Lösch, Dolores J Schendel
Journal of Translational Medicine|February 28, 2012
NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivoStefani Spranger, Bernhard Frankenberger, Dolores J Schendel
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Expert Opinion on Biological Therapy|January 26, 2007
Dendritic cell vaccine strategies for renal cell carcinomaDolores J Schendel
Haematologica|October 12, 2012
Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?Dolores J Schendel
Frontiers in Oncology|October 9, 2023
Evolution by innovation as a driving force to improve TCR-T therapiesDolores J Schendel
European Journal of Cell Biology|March 29, 2011
Third generation dendritic cell vaccines for tumor immunotherapyBernhard Frankenberger, Dolores J Schendel
Oncoimmunology|March 14, 2013
Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicityDolores J Schendel, Bernhard Frankenberger
Oncoimmunology|December 25, 2012
High-quality and high-avidity T cell clones specific for tumor-associated antigens and how to find themSusanne Wilde, Dolores J Schendel
Human Immunology|March 28, 2002
Allogeneic MHC class I ligands and their role in positive and negative regulation of human cytotoxic effector cellsChristine S Falk, Dolores J Schendel
Seminars in Cancer Biology|July 28, 2007
Immune suppression in renal cell carcinomaBernhard Frankenberger, Elfriede Noessner, Dolores J Schendel
Medical Sciences (Basel, Switzerland)|January 21, 2026
UniTope & TraCR: A Universal Tool to Tag, Enrich, and Track TCR-T Cells and Therapeutic ProteinsKanuj Mishra, Barbara Lösch, Dolores J Schendel
Journal of Translational Medicine|February 28, 2012
NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivoStefani Spranger, Bernhard Frankenberger, Dolores J Schendel
Pageof 9